文献速递间质性肺疾病

影像学纤维化范围在过敏性肺炎免疫调节治疗反应识别中的作用

Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis.
PubMed 文献 · Chest · 2025-12-18

这项回顾性队列研究纳入108例来自2个间质性肺病转诊中心、接受≥3个月免疫调节治疗的过敏性肺炎患者,按HRCT纤维化范围分为≥10%和<10%两组。结果显示,免疫调节治疗整体与12个月FVC轻度改善相关(+2.63%;95%CI 0.72-4.54;P<.01),纤维化<10%者FVC和DLCO均改善,而纤维化≥10%者未见改善。

要点

  • 纤维化<10%的过敏性肺炎患者免疫调节后FVC和DLCO均改善。
  • 纤维化≥10%的患者在12个月时FVC和DLCO均未见改善。
  • 影像学纤维化范围可能有助于过敏性肺炎治疗分层。

核心结论

  • 视觉纤维化范围与慢性过敏性肺炎患者对免疫调节治疗的肺功能反应差异相关。
  • 纤维化有限的患者肺功能改善,而影像学纤维化较多的患者未见改善。

研究设计与样本

  • 回顾性队列研究,纳入2个间质性肺病转诊中心的108例过敏性肺炎患者。
  • 患者接受≥3个月免疫调节治疗(泼尼松、硫唑嘌呤、霉酚酸酯和利妥昔单抗),治疗前后均行肺功能检查和HRCT。
  • 纤维化范围由盲法放射科医生判读,分为≥10%或<10%。
  • 采用线性样条混合效应模型估计FVC和DLCO占预计值百分比轨迹,患者自身对照。

主要发现

  • 整体免疫调节治疗与12个月FVC轻度改善相关(+2.63%;95%CI 0.72-4.54;P<.01)。
  • 纤维化<10%者免疫调节治疗后FVC改善(+5.83%;P<.01),DLCO改善(+13.9%;P<.01)。
  • 纤维化≥10%者在12个月时FVC未见改善(+0.81%;P=.42),DLCO未见改善(-4.3%;P=.17)。
  • 两纤维化组基线人口学特征、吸烟史和抗原识别状态相似。

关键数值与推荐

  • 纤维化范围分类阈值:HRCT视觉判读≥10%或<10%。
  • 免疫调节治疗疗程至少3个月。

临床怎么用

  • 纤维化范围可作为慢性过敏性肺炎免疫调节治疗分层的临床工具。
  • 纤维化有限的患者可能从免疫调节治疗中获得肺功能改善。

局限性

  • 回顾性研究设计。
  • 需要前瞻性试验验证影像学标志物指导过敏性肺炎管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment selection in chronic hypersensitivity pneumonitis (HP) remains empiric because of a lack of randomized trial data. Although radiographic fibrosis extent often is used to inform treatment decisions, its usefulness as a theragnostic marker for immunomodulatory therapy is unknown. RESEARCH QUESTION: Is visual fibrosis extent on high-resolution CT (HRCT) imaging associated with differential pulmonary function response to immunomodulation in chronic HP? STUDY DESIGN AND METHODS: This retrospective cohort study included 108 patients with HP from 2 interstitial lung disease (ILD) referral centers who received ≥ 3 months of immunomodulatory therapy (prednisone, azathioprine, mycophenolate mofetil, and rituximab) and had undergone pulmonary function testing and HRCT imaging before and after treatment. Fibrosis extent was classified as ≥ 10% or < 10% based on masked radiologist reads. Linear spline mixed-effects models were used to estimate FVC and diffusion capacity of the lungs for carbon monoxide (Dlco) % predicted trajectory before and after immunomodulation, with patients serving as their own controls. The primary analysis evaluated whether fibrosis extent modified the association between immunomodulation and lung function trajectory. RESULTS: Overall, immunomodulation was associated with a modest FVC improvement at 12 months (+2.63%; 95% CI, 0.72-4.54; P < .01). Among patients with < 10% fibrosis, immunomodulation was associated with improvements in both FVC (+5.83%; P < .01) and Dlco (+13.9%; P < .01). In contrast, no improvement in FVC (+0.81%; P = .42) or Dlco (-4.3%; P = .17) was observed in patients with ≥ 10% fibrosis at 12 months. Baseline demographics, smoking history, and antigen identification status were similar between fibrosis groups. INTERPRETATION: The results of this study indicate that visual fibrosis extent is associated with differential pulmonary function response to immunomodulatory therapy in chronic HP. Patients with limited fibrosis demonstrated improved pulmonary function compared with those with greater radiographic fibrosis. These findings may support the use of fibrosis extent as a clinical tool for treatment stratification and highlight the need for prospective trials to validate radiographic markers in guiding HP management.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Muegge CN, Min B, Mrad A, et al. Role of Radiographic Fibrosis Extent in Identifying Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis. Chest. 2025. PMID: 41421572. doi:10.1016/j.chest.2025.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。